
The Mount Sinai Institute for Exposomic Research is the nucleus of the Icahn School of Medicine’s work on studying how the environment affects human health. Our mission is to understand how the exposome, or the totality of our environmental exposures, affect health, disease, and development. We aim to translate our findings into new strategies for prevention and treatment. Our approach to exposomics is holistic, encompassing the chemical, nutritional, and social environments and the interrelationships among them. With our transdisciplinary research program and analytical capabilities, our scientists are designing innovative exposure measures and studying a vast array of health outcomes, such as childhood obesity, asthma, autism, learning disabilities, renal disease, cancer, postpartum depression, PTSD, and Lou Gehrig’s disease.

Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions. Our product range includes: Liquid and Gas Chromatography, Mass Spectrometry, Automated Liquid Handling, Atomic and Molecular Spectroscopy, Capillary Electrophoresis, Vacuum Technologies, Genomics, Cell Analysis, Liquid Handling/Automation

The exposome field now has its own journal. Exposome is published by Oxford University Press with Gary Miller serving as Editor-in-Chief. The journal is pleased to offer attendees of this year’s Exposome Symposium a 50% discount on our already low open access fees (normally $2000). Authors must submit their work by November 30, 2022 and mention the meeting in their cover letter.
This symposium is supported in part by:
Mount Sinai Human Health Exposure Analysis
Resource (HHEAR)
Lab Hubs and Data Center
(U2CES026561, U2CES026555)
(U2CES030859)
Mount Sinai
Environmental
Health Sciences (EHS)
Core Center
(P30ES023515)
Mount Sinai ConduITS
Clinical and Translational
Science Award (CTSA) Program
(UL1TR001433)